Charles River Laboratory is scheduled to release second-quarter earnings on August 5
Charles River Laboratories International announced that it will announce its second quarter 2026 financial results before the U.S. stock market opens on August 5. The company's management will hold a conference call at 9:00 a.m. that day to discuss performance and provide business commentary. Charles River Laboratories is the world's leading provider of drug R&D and non-clinical development services. Its business covers three major segments: research model production and sales, drug discovery and safety assessment services, and manufacturing solutions. It provides key products and services from early discovery to drug production to global pharmaceutical and biotechnology companies and academic institutions. The market's attention to this financial report is mainly focused on the key indicators previously guided by management. The company previously expected second-quarter reported revenue to decline by a mid-to-high single-digit percentage, with organic revenue declining by low-single digits; second-quarter earnings per share are expected to increase by at least 30% sequentially from the first quarter's $2.06. Analyst Zacks Research lowered its second-quarter earnings per share forecast to $2.72 from the previous $2.85 at the end of May, but still maintained its full-year outlook, predicting fiscal 2026 earnings per share of $10.91. The company previously reiterated full-year performance guidance for 2026, expecting organic revenue to decline 0.5% to 1.5% and non-GAAP earnings per share to be $10.80 to $11.30. Management also expects full-year operating margin expansion of approximately 120 to 150 basis points, with the majority of gains concentrated in the second half of the year. The company has previously completed the acquisition of K.F. Acquisition of Cambodian assets and PathoQuest, and divesting some non-core businesses to focus on core testing services and increase profit margins.